Intellia Therapeutics Inc Stock News

Cathie Wood purchased shares of Palantir, Tesla, and Intellia Therapeutics yesterday. She tends to buy some of her favorite stocks when they take a hit, but Palantir soared 31% on Tuesday after a well

Some of the top gene-editing stocks have had immense surge potential. Look at CRISPR Therapeutics (NASDAQ: CRSP ), for example.

The S&P 500 has increased about 35% in this new bull market -- but if history is a guide, gains have just gotten started. Past bull markets have lasted much longer than bear markets.

Intellia Therapeutics, Inc. (NTLA) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street an

The average analyst following Ginkgo Bioworks thinks the stock can climb 140% from recent prices over the next 12 months or so. The consensus price target on Intellia Therapeutics suggests it can more

Intellia Therapeutics has a promising candidate about to enter late-stage testing. The company has a couple of exciting earlier-stage programs, too.

Biotech stocks are some of the most exciting opportunities on the market.  Find the right ones with substantial catalysts and make a fortune.

Intellia Therapeutics is well capitalized, and moving into late-stage clinical trials. CRISPR Therapeutics will be raking in revenue and likely launching another therapy.

Intellia Therapeutics (NTLA) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Intellia Therapeutics and Editas Medicine are pre-revenue biotechs. Editas is a long way from commercializing its first medicine.

Intellia Therapeutics (NASDAQ: NTLA ) layoffs are a hot topic on Friday as the company prepares to cut jobs following an internal strategic review. According to a press release from Intellia Therapeut

Gene-editing companies are making headlines for the potential to reshape the future of healthcare and the treatment of hereditary diseases. The U.S. Federal Drug Administration (FDA) approved a sickle

The recent FDA approval of two gene therapies has put the focus on biotechs like EDIT, BEAM and NTLA, which have promising candidates in their pipeline.

Gene editing stocks have received a lot of attention throughout 2023. The intense focus on gene editing therapies and CRISPR technology is likely only to increase moving forward: The U.S. Food and Dru

Intellia and CRISPR Therapeutics both work in the field of gene editing. CRISPR Therapeutics just won regulatory approval for its first product, while Intellia recently entered late-stage development